Barclays PLC Zynerba Pharmaceuticals, Inc. Transaction History

Barclays PLC

  • $327 Billion
  • Q2 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$2.88 - $4.3 $20,931 - $31,252
-7,268 Closed
0 $0
Q3 2021

Nov 09, 2021
SELL
$3.72 - $5.35 $7,227 - $10,395
-1,943 Reduced 21.09%
7,268 $31,000
Q2 2021

Aug 13, 2021
BUY
$3.83 - $5.98 $32,447 - $50,662
8,472 Added 1146.41%
9,211 $49,000
Q1 2021

May 13, 2021
BUY
$3.33 - $8.76 $2,444 - $6,429
734 Added 14680.0%
739 $3,000
Q4 2020

Feb 11, 2021
SELL
$3.27 - $4.64 $14,715 - $20,880
-4,500 Reduced 99.89%
5 $0
Q3 2020

Nov 12, 2020
SELL
$3.23 - $4.3 $21,162 - $28,173
-6,552 Reduced 59.26%
4,505 $15,000
Q2 2020

Aug 12, 2020
SELL
$3.31 - $6.54 $3,925 - $7,756
-1,186 Reduced 9.69%
11,057 $37,000
Q1 2020

May 13, 2020
SELL
$2.9 - $6.16 $31,865 - $67,686
-10,988 Reduced 47.3%
12,243 $46,000
Q4 2019

Feb 10, 2020
BUY
$5.61 - $8.57 $31,892 - $48,720
5,685 Added 32.4%
23,231 $140,000
Q3 2019

Nov 14, 2019
SELL
$7.56 - $15.44 $352,704 - $720,337
-46,654 Reduced 72.67%
17,546 $131,000
Q2 2019

Aug 14, 2019
BUY
$5.4 - $15.5 $315,910 - $906,781
58,502 Added 1026.71%
64,200 $870,000
Q1 2019

May 15, 2019
SELL
$3.6 - $6.22 $96,235 - $166,273
-26,732 Reduced 82.43%
5,698 $31,000
Q4 2018

Feb 14, 2019
BUY
$2.89 - $7.91 $45,540 - $124,645
15,758 Added 94.52%
32,430 $96,000
Q3 2018

Nov 14, 2018
BUY
$5.59 - $10.45 $7,110 - $13,292
1,272 Added 8.26%
16,672 $136,000
Q2 2018

Aug 14, 2018
SELL
$7.98 - $12.39 $8,730 - $13,554
-1,094 Reduced 6.63%
15,400 $150,000
Q1 2018

May 15, 2018
BUY
$8.49 - $13.46 $58,954 - $93,466
6,944 Added 72.71%
16,494 $143,000
Q4 2017

Feb 14, 2018
BUY
$8.69 - $14.59 $32,352 - $54,318
3,723 Added 63.89%
9,550 $119,000
Q3 2017

Nov 14, 2017
BUY
$5.73 - $9.44 $33,388 - $55,006
5,827
5,827 $49,000

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email